Seroprevalence of SARS-CoV-2 in Croatian solid-organ transplant recipients

التفاصيل البيبلوغرافية
العنوان: Seroprevalence of SARS-CoV-2 in Croatian solid-organ transplant recipients
المؤلفون: Irena Tabain, Tatjana Vilibić-Čavlek, Vladimir Stevanović, Anna Mrzljak, Željka Hruškar, Jadranka Pavicic-Saric, Danko Mikulić, Ljubo Barbić, Željka Jureković
المصدر: Biochemia Medica
Volume 31
Issue 3
بيانات النشر: Croatian Society of Medical Biochemistry and Laboratory Medicine, 2021.
سنة النشر: 2021
مصطلحات موضوعية: Adult, medicine.medical_specialty, Short Communication, Clinical Biochemistry, COVID-19, seroprevalence, solid-organ transplant recipients, SARS-CoV-2 antibodies, medicine.disease_cause, Gastroenterology, Asymptomatic, Organ transplantation, Seroepidemiologic Studies, Interquartile range, Internal medicine, medicine, Humans, Seroprevalence, Pandemics, Coronavirus, biology, SARS-CoV-2, business.industry, Biochemistry (medical), Antibody titer, Organ Transplantation, Cross-Sectional Studies, Cohort, biology.protein, Antibody, medicine.symptom, business
الوصف: Introduction The data on the coronavirus disease (COVID-19) in solid-organ transplant recipients (SOTRs) in Croatia is unknown. The aim of this study was to analyze the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Croatian SOTRs. Materials and methods From 7 September to 27 November 2020 (beginning of the second COVID-19 pandemic wave), a cross-sectional screening for COVID-19 was performed in the adult outpatient liver (LTRs; N = 280) and kidney transplant recipients (KTRs; N = 232). Serum samples were initially tested for SARS-CoV-2 IgG antibodies using a commercial enzyme-linked immunosorbent assay (ELISA; Vircell Microbiologists, Granada, Spain). All positive samples were confirmed using a virus neutralization test (VNT). Data on risk exposure and COVID-19 related symptoms were collected using a questionnaire. Results The transplanted cohort's seroprevalence detected by ELISA and VNT was 20.1% and 3.1%, respectively. Neutralizing (NT) antibodies developed in 15.6% of anti-SARS-CoV-2 ELISA IgG positive SOTRs. The difference in seropositivity rates between LTRs and KTRs was not statistically significant (ELISA 21.1% vs. 19.0%, P = 0.554; VNT 3.6% vs. 2.6%, P = 0.082). Overall VNT positivity rates were higher in patients who reported participation in large community events (5.9% vs. 1.0%; P = 0.027) as well as in patients who reported COVID-19 related symptoms in the past six months. In addition, symptomatic VNT positive patients showed significantly higher (P = 0.031) NT antibody titers (median 128, interquartile range (IQR) = 32-128) compared to asymptomatic patients (median 16, IQR = 16-48). Conclusions This study showed that 15.6% of anti-SARS-CoV-2 ELISA positive Croatian SOTRs developed NT antibodies indicating protective immunity. Further studies are needed to determine the dynamic of NT antibodies and COVID-19 immunity duration in immunocompromised populations such as LTRs and KTRs.
وصف الملف: application/pdf
اللغة: English
تدمد: 1846-7482
1330-0962
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0a9ee55368b9f64ea1ff821a1dc4086Test
http://europepmc.org/articles/PMC8495621Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....f0a9ee55368b9f64ea1ff821a1dc4086
قاعدة البيانات: OpenAIRE